TechnoVax

TechnoVax is a privately-owned, near-clinical-stage biotechnology company based in the New York metropolitan area, specializing in viral vaccine development. Its mission is to develop unique and novel vaccine technologies that offer breakthrough clinical solutions with optimal efficacy and the highest safety standards, where no current alternatives exist.TechnoVax has developed a next-generation technology platform based on virus-like particles (VLPs), which can significantly enhance and expedite the development and production of countless vaccines targeting respiratory diseases as well as hemorrhagic fevers, immunodeficiency, and cancer. The vaccine pipeline has rapidly advanced into the clinical stage, featuring three main candidates: a universal flu vaccine, which would eliminate the need for annual flu shots and provide faster and better protection against future pandemic strains; an inhalable powder flu vaccine that requires no cold chain storage or distribution and can be self-administered—a solution urgently needed in developing countries.